The retinoic acid induced 1 (RAI1) gene when deleted or mutated results in Smith-Magenis syndrome (SMS), while duplication of 17p11.2, including RAI1, results in the dup(17)(p11.2) syndrome characterized by mental retardation, growth and developmental delays, and hyperactivity. Mouse models for these human syndromes may help define critical roles for RAI1 in mammalian development and homeostasis that otherwise cannot be deduced from patient studies. A mouse model for duplication, Dp(11)17 þ , involving Rai1 has been reported. However, this mutant was engineered on a mixed genetic background confounding phenotypic effects due to possible modifier genes. We have therefore created and evaluated mice with a graded series of four (hemizygous) and six (homozygous) copies of Rai1, and overexpressing Rai1 41.5-fold and 42-fold, respectively. Data show that Rai1-transgenic mice have growth retardation, increased locomotor activity, and abnormal anxiety-related behavior compared to wild-type littermates. Rai1-transgenic mice also have an altered gait with short strides and long sways, impaired ability on a cagetop hang test, decreased forelimb grip strength, and a dominant social behavior. Further, analyses of homozygous transgenic mice revealed a dosage-dependent exacerbation of the phenotype, including extreme growth retardation, severe neurological deficits, and increased hyperactivity. Our results show that Rai1 dosage has major consequences on molecular processes involved in growth, development, and neurological and behavioral functions, thus providing evidence for several dosage-thresholds for phenotypic manifestations causing dup(17)(p11.2) syndrome or SMS in humans.
Introduction
Smith -Magenis syndrome (SMS) and dup(17)(p11.2p11.2) are associated with reciprocal chromosome 17p11.2 rearrangements that include the retinoic acid induced 1 (RAI1) gene. 1, 2 SMS is characterized by mental retardation, craniofacial and skeletal abnormalities, speech and motor delays, sleep abnormalities, neurological and behavioral features, and obesity. 3 Recently, we determined that haploinsufficiency of RAI1 is responsible for most SMS features, while other genes in the SMS region contribute to the more variable features and overall severity of the phenotype. 2, 4 Patients with dup(17)(p11. 2) syndrome present with mental retardation, preand postnatal growth retardation, cognitive impairment, craniofacial abnormalities, heart defects, and hyperactivity. 1, 5 More than 40 patients with dup(17)(p11.2p11.2), ranging from 1.3 to 15 Mb in size, have been described. 1, 5 The critical region for the duplication has been narrowed down to approximately 1.3 Mb and also contains RAI1. 1, 5 So, it is likely that RAI1 plays a dosage-sensitive role contributing to both SMS and dup(17)(p11.2) syndrome. RAI1 (GenBank AY172136, AJ271790; OMIM*607642), which maps within the SMS region, is formed by six exons generating an approximately 8.5 Kb mRNA and a 1906 amino-acid protein. 6 The RAI1 protein contains a bipartite nuclear localization signal, polyglutamine and polyserine tracts, and a PHD/zinc-finger domain at the C-terminus. While polyglutamine and polyserine stretches have been shown to be involved in transcription, 7 the PHD domain in RAI1 is similar to that in the trithorax family of nuclear proteins that is involved in transcription-associated chromatin remodeling and transcriptional regulation. 8 RAI1 is highly conserved through vertebrate evolution. 9 Murine Rai1 (originally described as GT1) is upregulated in P19 embryonal carcinoma cells following treatment with retinoic acid to induce neuronal differentiation. 10 However, the exact functional role of RAI1 is not known.
To completely evaluate the phenotypic consequences of gene dosage for Rai1, BAC-transgenic mice containing two (hemizygous transgenic) or four (homozygous transgenic) additional copies of Rai1, were created. We tested these BAC-transgenic mice in a variety of experimental paradigms for physical, neurological, and behavioral phenotypes using a modified version of the SHIRPA (Smith Kline Beecham Pharmaceuticals, Harwell, MRC Mouse Genome Center and Mammalian Genetics Unit, Imperial College School of Medicine at St Mary's, Royal London Hospital, St Bartholomew's, and the Royal London School of Medicine Phenotypic Assessment) protocol, 11 -13 and a functional observational battery (F.O.B). 14, 15 Results indicate significant growth retardation, increased hyperactive behaviors, and impaired neurological and sensorimotor activity in Rai1 BAC-transgenic mice with a dosagedependent worsening of the phenotype with increased copies of Rai1. Our overexpression model taken together with other studies suggests that phenotypic consequences of Rai1 expression are associated with dosage thresholds for Rai1-specific biological processes, alteration of which leads to phenotypes associated with dup(17)(p11.2) syndrome and SMS.
Materials and methods
Creation of Rai1-transgenic mice A BAC clone, RP23-326M22 (GenBank accession AC096624), containing the entire mouse Rai1 gene, was chosen from a fully sequenced C57Bl/6J mouse genomic library. Rai1 BAC-transgenic mice were created as a fee for service at the University of Michigan Transgenic Animal Core. After using a modified Qiagen DNA isolation protocol for low-copy plasmids (Qiagen Inc., Valencia, CA, USA), 0.5 -1 ng/ml of purified, Not1-linearized BAC DNA was microinjected into the fertilized mouse eggs from two separate crosses: (C57Bl/6J Â SJL) F1 and (C57Bl/ 6J Â SJL) F1 or C57Bl/6J Â (C57Bl/6J Â SJL) F1, and eggs were transferred to recipient mothers. Three weeks following the microinjection, founder pups were born, genotyped, and later bred to C57Bl/6J females. Two male founders, C57BL/6J-Tg(RP23-326M22)1She (line 760) and C57BL/6J-Tg(RP23-326M22)2She (line 775), showed single, intact BAC site insertion into the genome and germ-line transmission of the BAC transgene. In addition to Rai1, the BAC also contains a sterol regulatory element binding protein (Srebp1) and 3 0 end of target of Myb-1-like-2 (Tom1l2). Transgenic lines were established and maintained by backcrossing to C57Bl/6J mice for more than six generations (499% C57Bl/6J background). The BACtransgenic mice are named according to the International Committee on Standardized Genetic Nomenclature for Mice (www.informatics.jax.org/). Mice (lines 760 and 775), carrying four or five copies of Rai1, respectively (single site insertion of two or three BACs, respectively), are termed 'hemizygous,' and progeny of F1 crosses of 760 hemizygotes are termed 'homozygous' throughout the manuscript.
Breeding and maintenance
Rai1 transgenic male founders were bred with C57Bl/6J female mice obtained from the JAX s -mice services (The Jackson Laboratory, Bar Harbor, ME, USA). For breeding, separate cages containing a transgenic male and 1 -2 C57Bl/6J females or a transgenic female and a C57Bl/6J male, or a transgenic male and a transgenic female were set up. The pups were genotyped, weaned, and separated based on sex at 3 weeks of age. Then, mice were housed 2 -5 per cage and had access to standard diet, Prolab s RMH 2000 (PMI Nutrition International Inc., Brentwood, MO, USA) and water ad libitum. The mouse room was maintained on a 12 h:12 h light:dark cycle, and all the tests, except the tests for circadian rhythm, were performed during the light phase. Ambient temperature (211C) and humidity (40%) were maintained. Animals used in our study were cared for in accordance with the guidelines of the Institutional Animal Care and Use Committee of Virginia Commonwealth University and the Guide for the Care and Use of Laboratory Animals (National Research Council, 1996) .
Genotyping of Rai1 BAC-transgenic mice Mice were genotyped by PCR analysis using template genomic DNA from mouse tails prepared using a standard phenol/chloroform procedure. PCR was carried out using two pairs of unique BAC-end specific primers. Primers SP6 F (5 0 -GATCCTCCCGAATTTCACTAGTG-3 0 ) and SP6 R (5 0 -TCCAGACTTGCTTGTGAACG-3 0 ) were used to amplify a 450 bp fragment unique to the SP6 end of the BAC transgene, and primers T7 F (5 0 -GGTCGAGCTTGACATTG TAG-3 0 ) and T7 R (5 0 -GGTAAGAAGTCCCCAGTCC-3 0 ) were used to amplify a 400 bp fragment specific to the T7 end of the BAC. As a control for DNA quality and wild-type animals, b-globin primers F (5 0 -CCAATCTGCTCACACAGG ATAGAGAGGGCAGG-3 0 ) and R (5 0 -CCTTGAGGCTGTCCA AGTGATTCAGGCCATCG-3 0 ) were used to amplify a 500 bp fragment. PCR was performed with 100 ng mouse tail genomic DNA, 20 pmol each of forward and reverse primers, 10 mM Tris-HCl, 50 mM KCl, 1.5 mM MgCl 2 , 200 mM dNTPs, and 1 U Taq DNA polymerase in a total reaction volume of 25 ml. Reactions were held at 941C for 5 min followed by 30 cycles of denaturing at 941C, 1 min; annealing at 601C (SP6 and T7)/591C (b-globin) for 1 min; and an extension at 721C, 1 min, followed by a final extension at 721C, 10 min. Reactions were held at 41C until use. The tail DNA from Rai1-transgenic mice showed amplification with SP6, T7, and b-globin primers, while DNA from the non-transgenic mice amplified with only b-globin primers.
Copy number evaluation of Rai1 BAC-transgenic mice Southern analysis To assess the copy number of the Rai1 gene in the transgenic mice, 3.5 mg of tail DNA from transgenic mouse and control DNA for the copy number standards were digested with 4 U of HindIII. Copy number standards were prepared by spiking control mouse DNA with appropriate amounts of BAC DNA, representing 1, 3, 5, or 10 copies of RP23-326M22, just prior to the digestion. All samples were electrophoresed in a 1% agarose gel, transferred to a nylon membrane, and hybridized to radioactive-labeled probes using standard protocols. The 3 0 end of an Rai1 cDNA clone (IMAGE: 1211624), a purified RP23-326M22 SP6-end PCR product, and a purified T7-end PCR product were used as probes. A densitometric analysis was done, standard curve derived, and the putative copy number was obtained from the line equation of the standard curves.
Real-time PCR TaqMan s copy number determination assays were performed using genomic DNA isolated from the livers of founder mice, 760 and 775, and other mice from these lines using the DNeasy kit (Qiagen, Germantown, MD, USA). Prior to the assays, serial dilutions of genomic DNA samples (100, 10, 1, 0.1, and 0.01 ng) from a C57Bl/6J mouse were prepared and used for validation of the method. A genomic DNA sample of a known non-transgenic mouse carrying disomic copies of Rai1 was used as a calibrator. For transgene amplification, a Taqman Rai1 (D29801) primer/probe set was used (Applied Biosystems, Foster City, CA, USA). A single-copy gene, glucagon, was used as an endogenous control with the primer/probe set sequences described previously. 16 All samples were run in triplicate in 20-ml reactions containing 2 Â TaqMan Universal PCR Master Mix (Applied Biosystems), primers at a final concentration of 900 nM each, 250 nM of the probe, and 50 ng of DNA. The PCR was run in the ABI Prism s 7900 HT Sequence Detection System (Applied Biosystems) using the following amplification parameters: 10 min at 951C, and 40 cycles of 15 s at 951C and 1 min at 601C. Delta delta C t ð2
ÀDDCt Þ method was used to compare the DC t (cycle threshold (C t ); C t of targetÀC t of control gene) value of transgenic animal samples with unknown transgene copy numbers with the DC t of a known calibrator.
Rai1 expression analysis in transgenic mice
Reverse-transcription and quantitative real-time PCR RNA samples were prepared from brain and liver tissues collected from both transgenic and non-transgenic animals using TRIzol reagent according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). Prior to reverse transcription, the RNA samples were treated with DNase I according to the manufacturer's instructions (Ambion Inc., Austin, TX, USA). The possibility of contamination with genomic DNA was eliminated by using 'no RT' controls in the reaction and also by performing a PCR using GAPDH primer sets amplifying across an intron. 17 First strand cDNA synthesis was carried out with 5 mg of total RNA and 1 ml oligo(dT) 12 -18 (500 mg/ml) using the MMLV reverse transcriptase protocol according to the manufacturer's instructions (Invitrogen). For quantitative real-time PCR, pre-designed Rai1 Taqman primers were used (Applied Biosystems). All samples were run in triplicate in 10-ml reaction volumes. PCR conditions were the default settings of the ABI Prism 7900 HT Sequence Detection System (ABI). The cycle threshold (C t ) was determined during the geometric phase of the PCR amplification plots, as recommended by the manufacturer. Relative differences in Rai1 transcript levels were quantified using the DDC t method with the glucagon mRNA as a gene loading control.
Phenotypic evaluation
All transgenic offspring were evaluated alongside their age and sex-matched non-transgenic littermates. Mice were subjected to a modified SHIRPA protocol consisting of an initial battery of tests adapted from SHIRPA, 13 the Irwin observational battery, 12 and the test battery described by Crawley and Paylor. 11, 18 All tests were performed in the same order for each mouse under appropriate behavioral testing conditions as described. For quantitative assessment of behavioral responses, mice were evaluated at 5, 10, and 20 weeks of age using a F.O.B. Two separate cohorts of mice were generated, one for the modified SHIRPA and the other for the F.O.B. The first cohort consisted of 35 Rai1 transgenic hemizygotes and 67 non-transgenic mice, and the second was composed of 13 Rai1 transgenic hemizygotes, 9 transgenic homozygotes, and 12 non-transgenic mice. The F.O.B. was originally described for rats, 14 but was later modified for mice. 15 It consists of a series of tests for noninvasive, rapid, and quantitative assessment of autonomic, sensory, and motor integrity in mice. F.O.B. experiments were conducted by an observer who was blinded to the genotypes of the mice. Detailed protocols for all the tests conducted, including circadian activity, histological and serum analyses are given in the Supplementary material. All phenotypic evaluations described are for Rai1 hemizygous transgenics unless otherwise noted. After the physical, behavioral and neurological evaluations, the mice were euthanized and dissected for gross examination of internal organs. Major organs (brain, heart, liver, spleen, kidneys, and thymus) were sectioned for histological assessments. All reported data were generated from the 760 line; however, the 775 line of mice showed similar results (Supplementary Figure S2 , Supplementary  Table S1 ).
Statistical analyses
Statistical analyses were performed using GraphPad Prism version 4.02 for Windows (GraphPad Software, San Diego, CA, USA). All data were analyzed for both males and females from each genotype (unless otherwise noted) using unpaired Student's t-test, and one-way (genotype) or twoway (genotype Â age) analysis of variance (ANOVA). Categorical data were analyzed using either Fisher's exact test or a w 2 test. Post hoc comparisons were made using Bonferroni's correction for multiple comparisons. The level of significance was set at Po0.05.
Results
Production of Rai1 BAC-transgenic mice A linearized BAC clone, RP23-326M22, containing Rai1 was used for microinjection of fertilized eggs. Forty-two live pups (17 females and 25 males) were initially analyzed by PCR for the presence of both (SP6 and T7) unique ends of the BAC vector ( Figure 1a ), resulting in five male founder mice positive for the Rai1-BAC transgene. Two of these founder mice showed single genomic site insertion and stable transmission of the BAC and were successfully mated to establish the transgenic lines 760 and 775. Rai1 transgenic pups were obtained from each of these lines at the expected Mendelian ratios. Similar phenotypes were observed for both lines, confirming the absence of position effects.
Copy number assessment and expression profile of Rai1-transgenic mice The copy numbers of BAC-transgenic mice were evaluated using a semi-quantitative Southern blotting technique and confirmed by a quantitative real-time PCR assay (qPCR) using Rai1-specific Taqman probes. Southern blotting, confirmed by copy number qPCR, showed that the Rai1 transgenic founders carry approximately four copies in the 760 line and five copies in the 775 line (Figure 1b and c).
Homozygous transgenic mice (evaluated and discussed later) with a total of six copies of Rai1 were obtained by breeding transgenic mating pairs from the 760 line ( Figure 1c ). Evaluation of cDNA derived from transgenic whole brain and liver using quantitative real-time PCR showed 450% increase in Rai1 mRNA levels in hemizygous transgenic mice ( Figure 1d ) and 4100% increase in homozygous transgenic mice (Supplementary Figure S1A) . Expression levels were also confirmed by western blots using protein lysates from transgenic whole brain and liver (Supplementary Figure S1B) .
General physical assessment
The transgenic mice were delivered at term and did not exhibit any obvious birth defects. Preliminary general physical examinations and tests for simple reflexes were conducted to identify and define the behavioral and functional profiles of Rai1-transgenic mice (Table 1) . Transgenic mice demonstrated overtly active, wild running behavior during the 30-min observational period compared to the non-transgenics (5/24 for transgenics versus 1/51 for non-transgenics, P ¼ 0.01; Fisher's exact test) ( Table 1) . Despite some variability between transgenics and non-transgenics, no intergroup difference emerged on any of the observations for abnormal grooming such as short/sparse whiskers (2/24 versus 3/51) and bald patches (1/24 versus 1/51), for simple reflexes such as the righting reflex, whisker response (2/24 versus 3/51), eye blink/ear twitch response, and pupillary response (Table 1) . Similarly, no autonomic (defecation, urination, lacrimation, and salivation) dysfunction was documented in the two groups (Table 1) .
Growth retardation in Rai1-transgenic mice The growth pattern of the transgenic line of pups along with their wild-type littermates was monitored by measuring body weights and lengths at 5, 10, 20, and 30 weeks of age. Rai1-transgenic mice weighed less than their wild-type littermates up to 20 weeks (Figure 2a) . A two-way ANOVA of body weights from the 760 line of mice showed significant effect of genotype (Po0.0001), age (Po0.0001), and genotype Â age interval interaction (Po0.0001). Overall, the male transgenic mice (Po0.05) were more growth retarded than the female transgenics. Furthermore, Rai1 transgenics were significantly shorter in length compared to their non-transgenic littermates; a two-way ANOVA on total body length showed significant effect of age (Po0.0001) and genotype (P ¼ 0.0002) (Figure 2b ). Thus, Rai1 transgenics have significant growth retardation early in life, but the body size normalizes by 20 weeks of age. At 30 weeks, the weights and lengths of transgenic mice were similar to those of non-transgenics. Neurological
11 Initially, rearing behavior or vertical activity of the mice were counted over a 5-min observation period. Rai1-transgenic mice displayed decreased rearing behavior compared to the non-transgenics at 10 weeks (Po0.05) and 20 weeks of age, although both genotypes exhibited similar numbers of rears at 5 weeks of age (Figure 3a) . Differences in rearing behavior have been associated with impaired anxiety-related responses, altered basal exploration, and abnormal motor coordination.
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A quantitative assessment of locomotor activity was performed in standard activity chambers interspersed with photocell beams (see Materials and methods). Total locomotor counts were measured and the center to total counts ratio was calculated. The transgenic mice showed significantly increased motor activity compared to nontransgenic littermates at ages 5 and 10 weeks (Po0.05) (Figure 3b) . At 20 weeks, the motor activity counts of transgenic mice normalized to those of non-transgenic mice. Since the Rai1 transgenics were hyperactive, the center to total counts ratio was used to correct for any confounding effects due to increased locomotor activity to assess anxiety-related responses. 11, 19 Measurement of center/total locomotor counts indicates that transgenic mice spend a lesser proportion of their exploration in the center of the open field as compared to non-transgenics (Figure 3c ). This finding demonstrates that transgenics avoid the center of the open field suggestive of higher anxiety levels.
Rai1-transgenic mice have impaired neuromuscular strength and coordination and hypersensitivity to pain To test for neuromuscular coordination, mice were subjected to a series of tests for strength and sensorimotor reflexes. The cage-top hang test evaluates neuromuscular grip strength and motor coordination. Here, the mice are allowed to hold on to the cage-top, which is then inverted over the cage. The amount of time (s) the mouse remains hanging is noted. The transgenic mice (at 20 weeks) easily fall off the cage-top and thus display an impaired neuromuscular ability (Po0.05) (Figure 3d , Table 1 ). Further supporting this, transgenic mice showed decreased ability to right themselves on an inverted screen compared to the non-transgenics ( Table 2 ). The hotplate test was performed to assess sensorimotor reflex response to a painful stimulus. Mice were placed on a hotplate (551C), and the latency to show their first hind Neurological and growth deficits in mice overexpressing Rai1 S Girirajan et al limb response was recorded. Although not statistically significant, transgenic mice were more sensitive to a painful stimulus with decreased latency to show their hind limb response compared to the non-transgenics (Table 1 , Figure 3e) . Similarly, transgenic mice demonstrated decreased latency on tail flick (Table 2, Figure 3f ). Thus, transgenic mice showed consistent trends toward hyperresponsiveness to sensory stimuli, as apparent in both paradigms, compared to the non-transgenics.
Nontransgenics
Physical assessment and simple reflexes (% abnormal) Whisker appearance 8 6 Bald patches (% with) 4 2 Nails, teeth, or genitalia 0 0 Righting reflex 0 0 Sound orientation 0 0 Whisker response 8 6 Eye blink/ear twitch 0 0 Pupil constriction/dilation 0 0 General observational measurement
Rai1 transgenics exhibit gait abnormalities
Gait tests were performed by foot-print analysis (see Materials and methods) at 20 weeks of age on both genotypes. The stride distance was significantly reduced in the transgenic mice (Po0.0001), while the sway distance was increased, resulting in a shorter, wider gait in the transgenics compared to the non-transgenics (Po0.0001) (Table 1, Figure 4) . Furthermore, transgenic mice have a shorter stance compared to the non-transgenics (Po0.0001). Abnormal gait could be due to reduced muscular tone, impaired cerebellar motor or peripheral neurological function, and/or due to an underlying musculoskeletal anomaly.
20,21
Social interactions and home-cage behaviors To evaluate social interactions, we used a tube test, a paradigm used to evaluate social dominance. 22 Mice were evaluated at 10 and 20 weeks of age and a total of 48 trials were conducted with 24 transgenics and 24 non-transgenics. Each transgenic mouse was tested twice with a different non-transgenic mouse (one from the same cage and another from a different cage) of the same gender. a different cage, and no gender or age-specific differences were observed. Although a confounding effect of hyperactivity cannot be excluded in the transgenics, our analysis suggests that transgenics are socially dominant compared to their wild-type littermates. Assessment of the nest building ability and homing behavior in both transgenic and normal littermates did not reveal any significant differences (Table 1) .
Circadian rhythm analysis
Wheel running activity was monitored for 24 h for 3 weeks in constant darkness (DD) after entrainment in a light:dark (12L:12D) cycle. Although circadian periods in transgenics were shortened by 6 min, overall there was no statistically significant difference in the average circadian period between the two genotypes (Supplementary Figure S4) .
Gross organ evaluations and histological and serum analysis
To identify any morphological or systemic organ anomalies due to Rai1 overexpression, postmortem dissections and histological analyses of transgenic and non-transgenic mice were performed. The gross anatomy of brain, liver, kidneys, spleen, heart, and thymus was unchanged in transgenic mice compared with their normal littermates (Supplementary Figure S5) . H and E staining of sectioned tissues did not reveal any visible difference in any of the organs examined with the exception of the transgenic liver sections, which showed a larger nucleus resulting in an increased nuclear:cytoplasmic ratio compared to the non-transgenic livers (Supplementary Figure S5) . Transgenic and non-transgenic mice were analyzed to identify any liver and metabolic abnormalities associated with Srebp1 overexpression, a gene also contained in the BAC. Analysis of serum showed no difference in the levels of liver enzymes (Supplementary Figure S6A) . Although there was an increase in the levels of cholesterol, triglycerides, and glucose in transgenic animals consistent with Srebp1 overexpression, 23 the difference was not statistically significant (Supplementary Figure S6B) . Since only 3 end of Tom1l2 is contained in the BAC, any potential effect of this gene was ruled out.
Rai1-transgenic mice exhibit dosage-dependent exacerbation of the phenotype To determine if there is an enhanced effect of the hitherto described Rai1 transgenic phenotype, we mated Rai1 hemizygous transgenic males and females to create Rai1 homozygous transgenic mice with six copies of Rai1 and 42-fold mRNA expression (Figure 1c) . The homozygous transgenic pups were obtained mainly by cross-fostering to non-transgenic mothers owing to the fact that the female transgenic hemizygotes had smaller litter sizes and few surviving pups. These mice were further evaluated for the Neurological and growth deficits in mice overexpressing Rai1 S Girirajan et al developmental, neurological, and behavioral paradigms described below (Table 2) . Visually, the Rai1 homozygous transgenic animals were slender, small-for-age, but very active and difficult to handle (Supplementary video; Table 2 ; Figure 5a ). Body weight and measurements were taken at 5, 10, and 20 weeks. A two-way ANOVA with the body weights indicates a significant growth retardation in the homozygous transgenic mice compared to the hemizygous transgenic and non-transgenic mice with significant effect of genotype (Po0.0001) and age (Po0.0001) (Figure 5a and b) . Preliminary evaluations of homozygous transgenic mice documented a significant hyperactive, possibly stressinduced behavior, which precluded testing for several behavioral paradigms, including inverted screen test, cage-top hang test, and social behaviors ( Table 2) . To illustrate this hyperactive behavior, the degree of difficulty in handling homozygous transgenic mice and the ease of removal of these mice from a cage were graded in an ordinal scale (Supplementary Figure S5A , B and Supplementary video). The observer experienced greater difficulty in handling the homozygous transgenics and in removal of these mice from the cage compared to the other genotypes (Supplementary Figure S7) . The majority of homozygous transgenics resorted to biting or squirming when handled (Table 2 ; Supplementary Figure S7) . Evaluation of locomotor activity in the Rai1 homozygous transgenic mice showed that the mean counts were significantly different from those of non-transgenics (Po0.05) but were similar to those of hemizygous transgenic mice (Figure 5b ). Forelimb grip strength was measured by using a strain gauge, and the force pulled (kg) was recorded. Results from forelimb grip strength test indicated a decreasing trend in neuromuscular function with homozygous transgenic mice showing Neurological and growth deficits in mice overexpressing Rai1 S Girirajan et al significantly low grip strengths (Po0.05) compared to the other genotypes (Figure 5c ). Furthermore, reduced rearing behavior among the homozygous transgenics was observed, although this was not significantly different from the hemizygous transgenics (data not shown). Thus, in these paradigms, the transgenic mice showed a dosage-dependent exacerbation of the phenotype (in order of increasing severity: non-transgenicsohemizygous transgenicsohomozygous transgenics), a trend consistent with increased Rai1 copy number.
Discussion
The use of transgenic mice has been beneficial to study the effect of overexpression or copy number variation of a single gene 24, 25 or a group of genes involved in segmental aneuploidy. 26, 27 While haploinsufficiency of RAI1 results in the majority of clinical features of SMS, its role in the reciprocal duplication 17p11.2 syndrome is not clearly understood. 4, 5 Human chromosome 17 is syntenic to a approximately 34-cM region of mouse chromosome 11, in which 19 genes are conserved in order and orientation. 28, 29 Mouse models for SMS and dup (17) (Table 3) . 30, 31 Studies showed that both the deletion 31, 34 and the Rai1 þ /À mice 30 manifested with craniofacial abnormalities, obesity, altered circadian rhythm, seizures, and hypoactivity, with the few viable Rai1 À/À mice exhibiting severe neurological abnormalities, motor dysfunction, overt seizures, and learning deficits (Table 3) . 33 Evaluation of the duplication mice showed hyperactivity, reduced weight, and impaired fear conditioning. 31 Although rescue of the phenotypes in both the deletion and the duplication mice was shown in the compound heterozygous (dup/del) mice, not all phenotypic features were rescued in the duplication/Rai1 þ /À mice (Table 3) . 29 Furthermore, these mice were created and evaluated in a mixed genetic background (C57BL/6 Tyr c-Brd Â 129S5/SvEBrd), resulting in incomplete penetrance for many of the traits observed, complicating the phenotypic analysis (Table 3) . 29, 30 To analyze the gene-dosage effect of Rai1, we created BAC-transgenic mice overexpressing the Rai1 gene in the C57BL/6J background (Figures 1 and 6 ).
Although the transgene expression pattern has not been tested in our mice, transgenesis was confirmed by expression and phenotypic analyses of two transgenic lines with Gait tests were not possible in homozygous mice because of extreme difficulty in handling.
Neurological and growth deficits in mice overexpressing Rai1 S Girirajan et al correspondence between expression levels and Rai1 copy number in both lines, controlling for any putative positional effect due to the integration site. 24 We did not anticipate any potential dosage effects of Srebp1 and Tom1l2 genes, which are also contained in the BAC, as no behavioral phenotypes have been associated with Srebp1 or Tom1l2 mice (Shimano, 2000; Girirajan et al, unpublished data).
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Rai1 hemizygous transgenic mice exhibit growth retardation prior to 20 weeks of age, while the homozygous transgenics remain small even after 30 weeks of age. Patients with SMS as well as individuals with dup(17)(p11.2) syndrome have a definitive delay in growth during early childhood. 1, 4 The growth deficiency observed in the transgenic animals is possibly due to an involvement of Rai1 in body energy and metabolic regulation; however, feeding behavior, neural regulation, and pituitary control of somatic growth cannot be ruled out. 35 Since Rai1 þ /À mice are obese and those overexpressing Rai1 are lean and growth retarded, mirroring the phenotypes observed in the corresponding human syndromes, there appears to be a direct correlation between Rai1 dosage and body mass, pointing to a conserved regulatory pathway between mouse and human. Further study is required to dissect its specific role. Craniofacial measurements of Rai1 transgenics showed significant sexual dimorphism, but no obvious difference between transgenics and non-transgenics was observed. This correlates with dup(17)(p11.2) patients who have subtle, sometimes difficult to discern, craniofacial features such as triangular face, microcephaly, hypertelorism, and broad nasal bridge; 1, 5 furthermore, the duplication mouse model, Dp(11)17/ þ , did not show any craniofacial anomalies. 31 Thus, increased copy number/overexpression of Rai1 has little to no effect on craniofacial development. Similarly, no major organ defect, evaluated by gross morphological or histological analysis on transgenic tissues, or circadian rhythm anomalies were observed in our transgenic mice, thus, corroborating the Dp(11)17/ þ data. 32 Spontaneous locomotor activity in the hemizygous transgenic mice is inversely correlated to body size with motor activity counts decreasing with age, normalizing at 20 weeks of age. Furthermore, the homozygous transgenic mice were hyperactive and so difficult to handle that evaluation for several behavioral paradigms was not possible. Correspondingly, dup(17)(p11.2) patients are hyperactive and are often diagnosed with attention-deficit hyperactivity disorder (ADHD). 5 A major consequence of extreme behaviors in homozygous transgenic mice was reduced fecundity in both males and females (Table 3 ). The transgenic mice spend less time hanging in the cage-top hang test and have reduced forelimb grip strength, while analysis of the responses to stimulus reactivity tests showed that the transgenic mice, in increasing order of Rai1 dosage, have altered sensorimotor coordination. To evaluate motor function and gaiting, gait tests were performed at 20 weeks to remove any confounding effects of body weight and size on gait pattern. The transgenic mice have an altered gait, with short strides, small stance, and abnormally wide sways, implicating Rai1 in cerebellar motor or neuromuscular function. Moreover, the Rai1 hemizygous and homozygous transgenics displayed exaggerated responses to handling, removal from cage, and arousal. Transgenics showed hypersensitivity to a painful stimulus and demonstrated reduced latency to tail-flick and hotplate tests compared to the non-transgenics. These data in mice are more consistent with altered RAI1 dosage directly influencing sensitivity and tolerance to pain as seen in patients with SMS and dup(17)(p11.2) syndrome. A review of the mouse models involving Rai1, including our present study, indicates that any alteration from the normal, disomic copy number of Rai1 results in impaired growth and development and neurological and behavioral phenotypes (Table 3) . Rai1 seems to have a global task in regulation of growth and development; however, its function in the predominantly expressed regions of the brain (including striatum, hippocampus, cerebellum, and the cerebral cortex) for modulating neurobehavioral endophenotypes is not clearly understood. 33 While downregulation of dopamine receptor genes in the striatum results in hyperactivity and spontaneous behavior in mice, decreased exploratory rearing activity has been associated with altered hippocampal oscillatory activity. 36, 37 Thus, Rai1 might play an important role in the hippocampus and striatal dopaminergic systems in modulating adaptive Figure 6 Rai1 dosage-thresholds and phenotypes due to altered Rai1 dosage. A graph representing Rai1 mouse models (Rai1 heterozygous knockout, Rai1 hemizygous BAC-transgenic, and Rai1 homozygous BAC-transgenic mice) on the x axis and increasing mean Rai1 expression levels or dosage on the y axis is shown. RAI1 dosage thresholds and associated human syndromes (Smith -Magenis and dup(17)(p11.2) syndromes) due to altered RAI1 levels are also shown below the x axis. The black shaded region represents RAI1/Rai1 levels at which no discernable phenotype is observed.
processes associated with exploratory and emotional behavior. 38 Gait abnormalities due to cerebellar dysfunction 39 or neurodegeneration have been reported in mouse models for lysosomal storage diseases, 40, 41 genes within the Down syndrome critical region, 42 genes encoding presynaptic proteins, 43 deficiency of transcription factors, 20, 21 musculoskeletal disorders, 44 and polyglutamine diseases. 45 Although the number of polymorphic polyglutamine repeats in human RAI1 is implicated in modulating the onset of spinocerebellar ataxia, 46 mice carry only four glutamines in this region, and polymorphic CAG repeats have not been reported. Our studies show that Rai1 modulates neurological and developmental processes in a dosage-dependent manner and plays a vital role in growth, development, and behavior. A recent report from Tbx1 mice also shows that there are many developmental process-specific thresholds for Tbx1 dosage beyond which the phenotype worsens. 47 Similarly, it is likely that Rai1 functions within a dosagewindow (black shaded region in Figure 6 ), deviation from which leads to phenotypic manifestations associated with SMS and dup(17)(p11.2) syndrome ( Figure 6 ). While homology studies have predicted a transcriptional role for Rai1, 7, 9 further investigations are necessary to understand the molecular targets and pathways in which Rai1 functions.
